Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 36,038	$ 25,470
General and administrative	7,199	5,948
Total operating expenses	43,237	31,418
Loss from operations	(43,237)	(31,418)
Other income:
Interest income	2,268	107
Other income, net	682	677
Change in fair value of CVR liability	1,700
Total other income, net	4,650	784
Net loss	$ (38,587)	$ (30,634)
Net loss per share attributable to common stockholders, basic	$ (0.55)	$ (0.68)
Net loss per share attributable to common stockholders, diluted	$ (0.55)	$ (0.68)
Weighted average common shares outstanding, basic	70,734,950	45,105,923
Weighted average common shares outstanding, diluted	70,734,950	45,105,923
Comprehensive loss:
Net loss	$ (38,587)	$ (30,634)
Other comprehensive loss
Net unrealized gains on marketable securities	120
Total other comprehensive loss	120
Comprehensive loss	$ (38,467)	$ (30,634)